Abstract
A 25-year-old man with RS rectal cancer received a radical resection of the original tumor and lymph node dissection. Oral tegafur/uracil (UFT)/Leucovorin (LV) therapy has been used for adjuvant chemotherapy, as the pathological Stage was T3N1M0, Stage IIIa. After 10 months from operation, multiple liver metastases were recognized and not resectable. So a systemic chemotherapy by mFOLFOX6+bevacizumab was begun via CV port. After 5 courses of mFOLFOX6+bevacizumab, abdominal CT revealed liver metastases showed remarkable reduction in size. Hepatic resection of S6 segment was enforced, and the patient uneventfully discharged. Pathological findings of S6 segment revealed no residual cancer cells, indicating the histological effect of mFOLFOX6+bevacizumab was Grade 3. And no liver damage was recognized.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Adult
-
Aged
-
Angiogenesis Inhibitors / administration & dosage*
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Bevacizumab
-
Colorectal Neoplasms / pathology*
-
Colorectal Neoplasms / surgery
-
Fluorouracil / administration & dosage
-
Humans
-
Leucovorin / administration & dosage
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / secondary*
-
Liver Neoplasms / surgery
-
Male
-
Neoplasms, Second Primary / drug therapy*
-
Neoplasms, Second Primary / secondary*
-
Organoplatinum Compounds / administration & dosage
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Organoplatinum Compounds
-
Bevacizumab
-
Leucovorin
-
Fluorouracil